New York, USA, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Ocular Hypertension Market Size and Share to Increase by 2032, Asserts DelveInsight | Leading Companies in the Market- Nicox, Glaukos, AbbVie, TearClear, Ocular, Perfuse
Several approved therapies such as EYBELIS, Durysta, Alphagan-P, Rhopressa, etc. will drive the current therapeutic landscape of ocular hypertension in the US, and the ocular hypertension market is estimated to increase by 2032. The primary reason for the ocular hypertension market growth will be the launch of the anticipated therapies, which will be a game changer to the current therapy market.
DelveInsight’s Ocular Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, ocular hypertension emerging drugs, market share of individual therapies, and current and forecasted ocular hypertension market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Ocular Hypertension Market Report
- As per DelveInsight’s analysis, the ocular hypertension market is anticipated to grow at a significant CAGR by 2032.
- According to Delveinsight’s estimates, in the year 2022, the total prevalent cases of ocular hypertension were approximately 21 million cases in the 7MM. The US accounted for the highest number of prevalent cases in the 7MM in 2022 which are anticipated to increase further by 2032.
- Leading ocular hypertension companies such as JeniVision, Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others are developing novel ocular hypertension drugs that can be available in the ocular hypertension market in the coming years.
- Some of the key therapies for ocular hypertension treatment include JV-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others.
Discover which therapies are expected to grab the major ocular hypertension market share @ Ocular Hypertension Market Report
Ocular Hypertension Overview
Ocular hypertension refers to elevated intraocular pressure, measuring over 21 mm Hg in one or both eyes, with no clinical signs of optic nerve damage or visual field defects. This condition is the primary risk factor for the development of glaucoma, making individuals with ocular hypertension more susceptible to the disease. Ocular hypertension risk factors consist of higher intraocular pressure, advancing age, a familial history of glaucoma, diminished ocular perfusion pressure (connected to both blood pressure and intraocular pressure), lower systemic blood pressure, thinner central cornea, and incidents of bleeding at the optic nerve head. Because OHT typically progresses to glaucoma without early warning signs, it often remains undetected until a comprehensive eye exam reveals elevated intraocular pressure through tonometry.
Ocular Hypertension Epidemiology Segmentation
The ocular hypertension epidemiology section provides insights into the historical and current ocular hypertension patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The ocular hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Ocular Hypertension Prevalent Cases
- Ocular Hypertension Gender-specific Diagnosed Prevalence
- Ocular Hypertension Age-specific Diagnosed Prevalence
- Ocular Hypertension Treated Cases
Download the report to understand which factors are driving ocular hypertension epidemiology trends @ Ocular Hypertension Epidemiological Insights
Ocular Hypertension Treatment Market
Presently, the ocular hypertension treatment market is segmented into various therapeutic classes, such as prostaglandin analogs, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, sympathomimetics, and miotics. Prostaglandin analogs (PGAs) are often the initial treatment choice for primary open-angle glaucoma (POAG) due to their effectiveness, minimal systemic side effects, and once-daily dosing. In March 2020, Allergan announced that the US FDA had granted approval for Durysta, a bimatoprost implant. This implant is noteworthy for being the first intracameral, biodegradable sustained-release option. Commonly prescribed prostaglandin analogs include Travatan, Vyzulta, and Zioptan. Before prostaglandins became the preferred choice, beta-blockers were widely used for managing glaucoma.
Epithelial cells located in the ciliary body express both beta-1 and beta-2 adrenergic receptors. When catecholamines interact with these receptors, it triggers the activation of cyclic adenosine monophosphate (cAMP), a secondary messenger that plays a crucial role in activating protein kinase A. This activation process results in the production and secretion of aqueous humor, which is an energy-dependent mechanism. Among the commercially available beta-blockers, timolol, levobunolol, and carteolol are nonselective, while betaxolol is cardioselective. Timolol, administered twice daily, is likely the most effective agent for lowering intraocular pressure (IOP), although levobunolol is equally effective and can be administered once daily with minimal differences in its effectiveness.
Learn more about the FDA-approved drugs for ocular hypertension @ Drugs for Ocular Hypertension Treatment
Key Ocular Hypertension Therapies and Companies
- JV-GL1: JeniVision, Inc.
- NCX 470: Nicox Ophthalmics, Inc.
- Kinezodianone R hydrochloride: Laboratoires Thea
- G2-TR intraocular implant containing travoprost: Glaukos Corporation
- H-1337: D. Western Therapeutics Institute, Inc.
- AGN-193408 SR: AbbVie
- Latanoprost ophthalmic solution: TearClear Corp
- OTX-TIC: Ocular Therapeutix, Inc.
- PER-001: Perfuse Therapeutics, Inc.
To know more about ocular hypertension clinical trials, visit @ Ocular Hypertension Treatment Drugs
Ocular Hypertension Market Dynamics
The dynamics of the ocular hypertension market are driven by a complex interplay of factors that reflect the evolving landscape of eye care and pharmaceuticals. Market dynamics are shaped by advances in diagnostic technologies, such as sophisticated tonometry and imaging devices, enabling earlier and more accurate detection of ocular hypertension. Additionally, the ocular hypertension market is influenced by a growing aging population, which is more susceptible to these conditions.
In terms of therapeutics, a shift towards personalized medicine and the development of innovative pharmaceuticals has spurred competition among pharmaceutical companies. The market is characterized by a steady stream of new medications and delivery methods, offering both physicians and patients more treatment options. Regulatory changes and healthcare policies also play a crucial role, affecting drug approval processes and pricing structures.
However, several factors may impede the growth of the ocular hypertension market. The stringent regulatory requirements for ocular hypertension and glaucoma medications can slow down the approval process. Meeting these standards demands substantial investments of time and resources, making it difficult for smaller pharmaceutical companies to enter the ocular hypertension market. The research and development costs associated with creating new medications and therapies can be exorbitant. This high financial barrier can deter companies from investing in this field, limiting innovation.
Moreover, disparities in access to healthcare, both in developed and developing countries, can limit the diagnosis and treatment of ocular hypertension. Access barriers may include financial constraints, geographic remoteness, or a lack of healthcare infrastructure. Additionally, a lack of awareness and understanding of ocular hypertension and its management can hinder early diagnosis and treatment. Increasing public and patient awareness is a critical barrier to address.
| Ocular Hypertension Report Metrics | Details |
| Study Period | 2019–2032 |
| Ocular Hypertension Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Ocular Hypertension Companies | Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., Betaliq, Inc., VivaVision Biotech, Inc., and others |
| Key Ocular Hypertension Therapies | JeniVision, Inc., Nicox Ophthalmics, Inc., Laboratoires Thea, Glaukos Corporation, D. Western Therapeutics Institute, Inc., AbbVie, TearClear Corp, Ocular Therapeutix, Inc., Perfuse Therapeutics, Inc., and others |
Scope of the Ocular Hypertension Market Report
- Therapeutic Assessment: Ocular Hypertension current marketed and emerging therapies
- Ocular Hypertension Market Dynamics: Attribute Analysis of Emerging Ocular Hypertension Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Ocular Hypertension Market Access and Reimbursement
Discover more about ocular hypertension drugs in development @ Ocular Hypertension Clinical Trials
Table of Contents
| 1. | Ocular Hypertension Market Key Insights |
| 2. | Ocular Hypertension Market Report Introduction |
| 3. | Ocular Hypertension Market Overview at a Glance |
| 4. | Ocular Hypertension Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Ocular Hypertension Treatment and Management |
| 7. | Ocular Hypertension Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Ocular Hypertension Marketed Drugs |
| 10. | Ocular Hypertension Emerging Drugs |
| 11. | Seven Major Ocular Hypertension Market Analysis |
| 12. | Ocular Hypertension Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Ocular Hypertension Epidemiology Forecast
Ocular Hypertension Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted ocular hypertension epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Ocular Hypertension Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key ocular hypertension companies, including Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, LLC, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea, among others.
Hypertension Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypertension companies, including Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision, Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics, Inc., Aadi Bioscience, Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma, LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio, Inc., Santen Pharmaceutical, VivaVision Biotech, Mitsubishi Chemical Group Corporation., Idorsia Pharmaceuticals, United Therapeutics Corporation, VIVUS LLC., PhaseBio Pharmaceuticals, Vascular Biosciences, CAR peptide, Liquidia Corporation, Centessa Pharmaceuticals, Claritas Pharmaceuticals, Halo Biosciences, PulmoSIM Therapeutics, Keros Therapeutics, among others.
Pulmonary Hypertension Pipeline
Pulmonary Hypertension Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary arterial hypertension companies, including Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, Dong-A ST, Mezzion, Northern Therapeutics, Merck Sharp & Dohme Corp., Apeiron Biologics, VIVUS, Respira Therapeutics, Resverlogix, Bial - Portela C S.A., Vigonvita Life Sciences, Altavant Sciences, Roche, PhaseBio Pharmaceuticals, Gossamer Bio, Reviva Biopharmaceuticals, Cereno Scientific, Attgeno, Rho Federal Systems Division, Inc., Cumberland Pharmaceuticals, AstraZeneca, Aerovate Therapeutics, Celon Pharma, Camurus, ATXA Therapeutics, Gmax Biopharma, Aerami Therapeutics, Pfizer, Aadi Biosciences, SystImmune, Claritas Pharmaceuticals, Reviva Biopharmaceuticals, Aqualung Therapeutics, Pulmokine, Recursion Pharmaceuticals, among others.
Pulmonary Arterial Hypertension Pipeline
Pulmonary Arterial Hypertension Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary arterial hypertension companies, including Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
